AI assistant
GILEAD SCIENCES, INC. — Director's Dealing 2014
Aug 28, 2014
29828_dirs_2014-08-28_11471692-2ce2-499d-a184-c217e34a6ce5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GILEAD SCIENCES INC (GILD)
CIK: 0000882095
Period of Report: 2014-08-26
Reporting Person: Carter Paul Rutherford (EVP Commercial Ops)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-08-15 | Common Stock | A | 259 | $21.9449 | Acquired | 32244 | Direct |
| 2014-08-26 | Common Stock | M | 10000 | $19.085 | Acquired | 42244 | Direct |
| 2014-08-26 | Common Stock | S | 10000 | $106.1618 | Disposed | 32244 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-08-26 | Non-Qualified Stock Option (right to buy) | $19.085 | M | 10000 | Disposed | 2021-01-20 | Common Stock (10000) | Direct |
Footnotes
F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan..
F2: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
F3: Sale prices reported for the transactions reported here range from $105.835 to $106.35. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.